Background The etiologic profile of community-acquired pneumonia (CAP ... infections by conventional bacteria result in higher severity, and the S. pneumoniae remains the most important pathogen.

Lefamulin is a novel antibiotic that has recently gained attention for its effectiveness in treating community-acquired bacterial pneumonia (CABP). As antibiotic resistance continues to rise ...

and their efficacy and safety in the management of community-acquired pneumonia (CAP). Data show that CAP is a common presentation in primary care practice, and is associated with high rates of ...

There are more than seven main types of pneumonia, including community-acquired pneumonia caused by bacteria and viruses. Other types include walking, aspiration, chemical, and hospital-acquired ...

Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults ...

They don’t have the infection when they're first admitted, but acquire it later after being exposed to bacteria in the ...

For Cresemba, this comprises a milestone payment for sales in Canada, by AVIR Pharma Inc, as well as the first sales milestone payment for the Middle East and North Africa (MENA) region, by Hikma ...